Pfizer Showcases New Data Across its Broadened Oncology Portfolio at ASCO Annual Meeting

With one in five people facing a cancer diagnosis in their lifetime, the disease touches everyone’s life in some way. If the numbers tell us anything, it’s that cancer isn’t slowing down – and neither is Pfizer.  

Pfizer has made significant investments to drive the next wave of treatment advances in cancer, creating a new Oncology organization with industry-leading scientific expertise, an expanded portfolio and the global scale to reach as many patients as quickly as possible. Pfizer scientists are using their deep technical expertise to develop next-generation cancer therapies that span three core modalities to attack cancer from multiple angles: small molecules, antibody-drug conjugates (ADCs) and immuno-oncology (IO) biologics, including bispecific antibodies.

Our vision is a world where people with cancer live better and longer lives, and at the American Society for Clinical Oncology (ASCO) Annual Meeting this week, we will present new data across our portfolio, demonstrating our progress toward making this vision a reality.

“We are on the cusp of a new era in cancer care – and Pfizer is accelerating the development of potential breakthrough cancer medicines to bring hope to patients everywhere,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization. We’re looking forward to key data presentations across our newly expanded portfolio, including additional evidence reinforcing the benefit of several approved medicines as well as promising new data from our deep and diverse pipeline.”  

All told, Pfizer will present more than 50 company-sponsored abstracts at the ASCO Annual Meeting, including 11 oral presentations. The data span the company’s four tumor areas of focus – breast cancer, genitourinary cancer, hematology-oncology and thoracic cancers – as well as additional tumor types including gynecological and gastrointestinal cancers. Several presentations will share important data highlighting the long-term impact of our medicines for patients, including new five-year follow-up results from a study evaluating our third-generation medicine for a molecular sub-type of lung cancer.

We know that medicines can’t save lives if they can’t reach the people who need them. Pfizer has a long history of working collaboratively across the Oncology community to address barriers to access, tackle inequities in care and meet patients and healthcare providers where they are.

“As we continue to drive our cutting-edge science forward, patients remain at the center of everything we do,” said Karin Tollefson, Chief Oncology Medical Officer, Pfizer. “The ASCO Annual meeting is an important opportunity for us to continue to listen and learn from healthcare providers and patient advocates. Through ongoing partnership with the scientific and advocacy community, we will continue to drive toward our shared goal of ensuring patients who need our medicines can benefit from the latest scientific advancements in cancer care.”

Click here to follow along with the latest news from Pfizer at the ASCO Annual Meeting.